39 results about "Phosphonatase" patented technology

The present invention provides methods, compositions, and kits for the treatment of matrix mineralization disorders such as hypophosphatasia. In particular, the present invention provides polypeptides having a soluble alkaline phosphatase fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to patients, e.g., subcutaneously, to treat hypophosphatasia using enzyme replacement therapy. The invention also features nucleic acids encoding such polypeptides and the use of the nucleic acids for treating matrix mineralization disorders.

The invention provides a method for producing 1,3-propylene glycol through fermentation via recombinant microbes. According to the invention, an endogenous dihydroxypropanone phosphatein phosphatase gene hdpA is over-expressed in Corynebacterium glutamicum to reinforce removal of phosphoric acid from dihydroxypropanone phosphatein so as to produce dihydroxypropanone; exogenous glycerol dehydrogenase is introduced to convert dihydroxypropanone into glycerin; and glycerin finally produces 1,3-propylene glycol under the action of exogenous glycerol dehydratase and an activator thereof and alcohol dehydrogenase. Corynebacterium glutamicum can use different cheap raw materials for fermentation, and cheap corn steep liquor can be used as a nutritional component to replace expensive yeast powder, so cost for raw materials is further reduced, and the problems in biosecurity and tolerance of the bacterial strain to a substrate and a product are overcome; and thalli obtained in the process of fermentation can be used as a product for a feed additive. The method provided by the invention produces few by-products and can further simplify the separating process of 1,3-propylene glycol.

The invention discloses an oleanane-type triad compound, and also provides its preparation method and medical application. Acid phosphatase 1B activity of oleanane-type (oleanane-type) triad compounds, structure: R1 is hydroxyl, acetoxy, R2 is carboxyl, hydroxymethylene, R3 is methyl, carboxyl, R4 For carboxyl, methyl. Multiple in vitro protein tyrosine phosphatase 1B inhibition experiments show that the compound has obvious PTP1B inhibitory activity and can be used in the preparation of medicines for diabetes, obesity and complications.

The invention relates to the technical field of microbial fermentation, and in particular relates to a recombinant microorganism for producing sialic acid and application of the recombinant microorganism. Compared with a starting strain capable of synthesizing sialic acid, the recombinant microorganism provided by the invention has increased expression of 6-phosphoglucosamine synthetase or a mutant thereof and increased expression of fructose-1,6-diphosphate esterase and / or glutamine synthetase. According to the invention, the recombinant microorganism capable of producing sialic acid by taking cheap carbon sources, such as glucose and glycerol, as raw materials through fermentation is obtained by modifying the microorganism; the sialic acid yield of the recombinant microorganism is remarkably improved; efficient conversion from the cheap carbon sources, such as glucose and glycerol, to sialic acid is realized; the production cost of sialic acid is remarkably reduced; and the recombinant microorganism has important industrial application value.

The invention relates to methylated proteins that control protein phosphorylation, particularly phosphoesterases, such as PP2A. It relates to screening methods for determining agents that affect methylation of these proteins and thus also modulate the level of phosphorylation of phosphoproteins. It relates as well to the agents and to compositions comprising the agents. In a particular aspect in this regard the invention relates to agents that alter PP2A methylation and that thereby affect phosphorylation of phosphoproteins that play an important role in health or disease, such as the tau protein which is implicated in the etiology of Alzheimer's Disease. The invention further relates to diagnostic methods based on protein methylation levels, to compositions comprising agents for affecting methylation of proteins and for controlling the phosphate complement of phosphoproteins. Additionally, the invention relates to methods for administering the agents and compositions to affect methylation of proteins physiologically and to modulate the phosphate complement of phosphoproteins. Examples in this regard include agents and compositions that affect physiological activity of PP2A and alter the phosphate complement of phosphoproteins that are altered in disease.

The invention relates to a biphenyl methylene-2-sulpho-4-thiazolone compound with a structure shown in the general formula (I), and a preparation method and application of the compound, as well as a medicine composition containing the compound. A biological activity test proves that the compound can obviously inhibit the activity of protein tyrosine phosphatase (PTP)-1B. Therefore, the biphenyl methylene-2-sulpho-4-thiazolone compound disclosed by the invention can be used as an inhibitor for the PTP-1B for preventing or symptomatically treating diabetes mellitus or adiposis.

A method of enzymatic degradation of hydrolyzed nerve agents GB, GD, GF, VX and O-isobutyl S-(diethyl-aminoethyl) methylphosphonothioate into biodegradable methylphosphonate products using enzymes from bacteria that can use for growth as the sole phosphorus source, low concentrations of ethyl-isopropyl-, and pinacolyl methylphosphonates (EMPn, IMPn, and PMPn-alkali treatment products of VX, GB, and GD, respectively).

The invention relates to a chestnut shell extract as well as a preparation method and application thereof, and belongs to the technical field of natural product extraction and application. The preparation method comprises the following steps of: extraction, namely performing solvent extraction by using chestnut shells as a raw material and using a 40-100% ethanol aqueous solution as a solvent, and recovering the solvent, thus obtaining the chestnut shell extract. The chestnut shell extract has the effect of inhibiting protein tyrosine phosphatases 1B (PTP1B), and the extract can be used as a PTP1B inhibitor for treating diabetes, obesity and other complications.

The invention discloses a composite organophosphorus degrading enzyme biological decontamination agent for emergency rescue and decontamination operation at chemical disaster accident environmental scene. The decontamination agent mainly consists of organophosphorus hydrolase, organophosphorus anhydride hydrolase, diisopropyl fluorine phosphatase, organochlorine degrading enzyme and trehalose, wherein all the components reach the following contents in percentages: 80-90% of organophosphorus hydrolase, 3-5% of organophosphorus anhydride hydrolase, 2.5-3% of diisopropyl fluorine phosphatase, 5-10% of organochlorine degrading enzyme and 0.5-1% of trehalose. The decontamination agent has the following advantages: compared with traditional chemical, physical and mechanical decontamination modes, the composite organophosphorus degrading enzyme biological decontamination agent has such advantages as no poison, no corrosion, high catalysis efficiency, low use level and wide application range, can be used for decontamination and disinfection for staff, clothes, equipment, soil and water sources polluted by organophosphorus, organochlorine and sulfides, in particular, is suitable for emergency rescue and decontamination in pesticide leakage accident scenes, and cannot cause secondary environmental pollution.

The invention discloses a birch bark extractive as well as an extraction method and medical purposes thereof. The extraction method comprises the following steps of: extracting and separating birch bark to obtain a component with the resistance to PTP1B (Protein Tyrosine Phosphatase 1B) activity. Shown by multiple in-vitro restriction experiments of the PTP1B, the component has remarkable PTP1B restriction activity and can be applied to preparing medicaments for treating diabetes, obesity and complications.

The present invention discloses one kind of composite flour additive and its preparation process. The composite flour additive consists of sodium vitamin C phosphate 10-80 weight portions, phosphatase 1-10 weight portions and corn starch 10-90 weight portions. Its preparation process includes the steps of inspecting the materials, 80 mesh sieving of the materials, and mixing in a mixer to obtain the product. The composite flour additive has sodium vitamin C phosphate and phosphatase as the fast oxidant and slow oxidant adopted simultaneously and can release oxidant vitamin C slowly to oxidize the dough in the use effect similar to that of oxidant potassium bromate.

Production of 1,3-dihydroxy-5-alkylamine compound with protein tyrosine phosphatase 1B inhibiting activity extracted and separated from branches and leaves of Lumnitzera racemosa Willd and its use are disclosed. R1 and R2 is H or Ac, R3 is H or CH3, n=8 or 10. It is carried out by drying and breaking branches and leaves of Lumnitzera racemosa, extracting by methyl alcohol, extracting the subsection of light petroleum, acetic ether and (n-)butanol, silica gel column and Sephadex LH-20 gel column chromatographing the part of acetic ether, separating to obtain monomer compound, analyzing by wave spectrum, determining 1,3-dihydroxy-5-alkylamine compound, acetylating and methylating reacting, and obtaining acetylate and methylate. It has PTP1B inhibiting activity and can be used for diabetes mellitus and obesity.

The invention relates to the technical field of medicinal compounds, and particularly discloses a new compound 3-oxo-21 beta, 23-diahydoxyolean-12en-28-oic acid extracted and separated from parthenocissus tricuspidata, and an application of the new compound in preparation of an anti-diabetic drug. Modern spectrum technologies such as 1D-NMR, 2D-NMR, high-resolution mass spectrum and the like are adopted to carry out structure identification on the separated monomeric compound, and the molecular structure of the compound is derived. An enzyme activity experiment result shows that the new compound has better activity of inhibiting protein tyrosine phosphatase 1B (PTP1B) and alpha-glucosidase. Molecular docking results show that the new compound has good binding activity with a target protein, and the interaction force is mainly hydrogen bonds and hydrophobic forces. The new compound has a good hypoglycemic effect, and has a good application prospect in the aspect of treating diabetes mellitus.

The invention relates to an anthraquinone / coumarin dimer novel skeleton compound, and a preparation method and application thereof. The structural formula of the dimer compound is shown in the specification. Anthraquinone and coumarin are coupled through a methylene carbon bridge to form the compound with a novel skeleton. The compound can efficiently and highly selectively inhibit the activity of protein tyrosine phosphatase 1B. The invention relates to the compound, the preparation method thereof and application of the compound in preparation of PTP1B inhibitors, medicines for treating type 2 diabetes mellitus and antitumor medicines.

The invention aims to extract alkaline phosphatase (ALP) from food-grade strain lactic acid bacteria, apply the ALP to degradation of pesticide glyphosate, and explore the mechanism of the alkaline phosphatase for promoting the degradation of the glyphosate pesticide and the interaction mode of the ALP and the glyphosate pesticide by using a computer-aided molecular simulation technology. The invention develops a method for degrading glyphosate pesticide by using lactobacillus alkaline phosphatase.

The invention relates to the technical field of medicinal compounds, and particularly discloses a new compound 3beta, 23-dihydroxy-28-norolean-12-ene-16-one extracted and separated from parthenocissustricuspidata, and an application of the new compound in preparation of an anti-diabetic drug. Modern spectrum technologies such as 1D-NMR, 2D-NMR, high-resolution mass spectrum and the like are adopted to carry out structure identification on the separated monomeric compound, and the molecular structure of the compound is derived. An enzyme activity experiment result shows that the new compound has better activity of inhibiting protein tyrosine phosphatase 1B (PTP1B) and alpha-glucosidase. Molecular docking results show that the new compound has good binding activity with a target protein, and the interaction force is mainly hydrogen bonds and hydrophobic forces. The new compound has a good hypoglycemic effect, and has a good application prospect in the aspect of treating diabetes mellitus.

The invention provides a novel 1,3-diaryl pyrazole compound containing a carboxyalkyl rhodanine structure or a pharmaceutically acceptable salt of the compound as a novel protein tyrosine phosphatase1B (PTP1B) inhibitor. Studies show that the inhibitor of this type can effectively inhibit PTP1B activity and can be used as an insulin sensitizer for preventing and / or treating related diseases withinsulin resistance mediated by PTP1B, especially type II diabetes and obesity. The invention also provides a preparation method of the inhibitor.

The invention relates to cordyceps militaris polypeptide as well as a preparation method and applications of the cordyceps militaris polypeptide, belonging to the technical field of bioactive polypeptide. The preparation method of the cordyceps militaris polypeptide comprises the following steps: (1) carrying out degreasing, namely, taking cordyceps militaris, adding degreasing fluid into the cordyceps militaris, carrying out heating reflux for 1-4h at 50-80 DEG C for degreasing treatment, carrying out filtering, and carrying out drying on the filter residues for later use; and (2) carrying out enzymolysis, namely, respectively taking the filter residues, adding water into the filter residues according to the ratio that 8-25mL of water is added into each gram of filter residues, adjusting the pH value of the solution, adding with pepsase, trypsin or neutral protease, carrying out enzymolysis for 2-6 h at 30-40 DEG C, heating the enzymatic hydrolysate for inactivating the enzyme, carrying out cooling, and carrying out filtering, thus obtaining the cordyceps militaris polypeptide. The cordyceps militaris polypeptide component prepared by adopting the method has the effect of inhibiting protein tyrosine phosphatase 1B (PTP1B), and can be used for treating the diseases including insulin resistance and diabetes. Cordyceps militaris realizes the homology of medicine and food, the enzymolysis active peptide prepared by adopting the method is directly extracted from cordyceps militaris, and has the advantages of low toxicity, high safety, and long-term administration availability.

The invention discloses application of pseudomonas chlororaphis to prevention and control of clubroot of cruciferae crops, and belongs to the field of microorganisms. The invention provides a biocontrol bacterium MCNB07405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), is classified and named as Pseudomonas chlororaphis, has a preservation number of CGMCC NO: 24326, is located at Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and has a preservation date of January 17, 2022. Experiments prove that the biocontrol bacterium has the activity of phosphoesterase and cellulase, the biocontrol bacterium has the potential of a biocontrol bacterium agent, the bacterium agent can prevent and treat the cabbage clubroot, the prevention and treatment effect is 56.8%, and it is indicated that the strain or the biocontrol bacterium agent has good market application prospects in the field of prevention and treatment of the clubroot of cruciferae crops.

The invention discloses a metal phosphoesterase, a carrier thereof, a storage solution and a preparation method, the amino acid sequence of the metal phosphoesterase is shown as SEQ ID NO: 1, and the metal phosphoesterase has the activity of the metal phosphoesterase; or the nucleotide sequence is SEQ ID NO: 2 or the coded amino acid sequence is a nucleotide sequence as shown in SEQ ID NO: 1. According to the technical scheme, an escherichia coli expression system is adopted in the preparation process of the metal phosphatase, expression conditions and purification conditions are optimized, the active metal phosphatase which is low in cost, high in purity, high in yield and high in stability can be obtained in the shortest production period, and the metal phosphatase has wide market application prospects. The metal phosphoesterase expressed through recombination can be used for decomposing glycerol-oriented or alcohol-oriented phosphodiester bonds in vitro, and has wide application prospects in the aspects of biological pharmacy, clinical treatment of certain lipoprotein abnormality related diseases, hydrolysis of certain lipoproteins, synthesis of phosphatidic acid, use of the metal phosphoesterase as an emulsifier in industrial production and the like.